The FDA adaptive trial design guidance (1) is a thoughtful but lengthy document that explains on 50 pages wide-ranging and important topics "such as ... what aspects of adaptive design trials (i.e., clinical, statistical, regulatory) call for special consideration, ... when to interact with FDA while planning and conducting adaptive design studies, ... what information to include in the adaptive design for FDA review, and ... issues to consider in the evaluation of a completed adaptive design study." [20] [21] [22] [23] [24] . The advice in the guidance is often misinterpreted, misquoted or ignored. This is unfortunate because an appropriate use of adaptive designs could increase the chances of success in drug development programs. Decision makers rely on the advice of regulatory affairs professionals and statisticians to interpret the guidance. Unfortunately, many clinical trial statisticians and regulatory professionals only have a rudimentary understanding of the guidance, presumably because the document is somewhat inscrutable for both audiences, too 'regulatory' for statisticians, too 'statistical' for regulatory people. This digest was therefore written with three goals in mind: 1) Make the content of the guidance more accessible through a question & answer format, 2) shorten the content from 50 to 10 pages by excerpting the most important dictums, and 3) keep fidelity to the original guidance by frequent use of direct quotes with reference to the respective lines in the original FDA guidance where the quote can be found in square brackets.
WHAT IS THE FOCUS OF THE GUIDANCE?
Adequate and well-controlled studies intended to provide substantial evidence of effectiveness required by law to support a marketing application [53-56, 180 -182], abbreviated as 'A&WC studies'.
HOW DOES FDA DEFINE AN ADAPTIVE TRIAL DESIGN?
For the purposes of the guidance, "an adaptive design clinical study is defined as a study that includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and hypotheses based on analysis of data (usually interim data) from subjects in the study" [66-69] in a blinded or unblinded manner [70] [71] .
WHAT TYPES OF STUDIES ARE NOT CONSIDERED ADAPTIVE DESIGNS?
Revisions after unplanned findings in an interim analysis [541] and revisions based on information from a source external to the study [553] , called in the guidance a 'reactive revision' [563] . However, see also Question 4. Yes. All less well understood adaptive designs involve unblinding, however, not all unblinded interim analyses are less well understood. The guidance states "other adaptive methods use the wellunderstood group sequential design ... in group sequential designs, unblinded interim analyses of accruing study data are used in a planned and confidential manner (i.e., by a DMC) that controls Type I error and maintains study integrity" [602 -604] . A reference is made to section D, implying that this statement specifically applies to futility analysis.
WILL REACTIVE REVISIONS BASED ON
The guidance elaborates on the topic of futility analysis in the following under section V. D.: "Group sequential statistical design and analysis methods have been developed that allow valid analyses of interim data and provide well-recognized alpha spending approaches to address the control of the Type I error rate (e.g., O'Brien-Fleming, Lan-DeMets, Peto methods) to enable termination of a study early when either no beneficial treatment effect is seen or a statistically robust demonstration of efficacy is observed" [772] [773] [774] [775] [776] [777] . The remainder of the section discusses several well-known caveats, most of which concern protection of the study integrity.
ARE GROUP-SEQUENTIAL DESIGNS
THAT 
WHEN DO I HAVE TO HAVE THE INTERIM ANALYSIS PLAN FINALIZED?
If unblinding is involved the plan needs to be finalized before unblinding occurs but not necessarily before the study starts. "The term prospective here means that the adaptation was planned (and details specified) before data were examined in an unblinded manner by any personnel involved in planning the revision. This can include plans that are introduced or made final after the study has started if the blinded state of the personnel involved is unequivocally maintained when the modification plan is proposed" 
DOSE SELECTION STUDIES
"An adaptive exploratory dose-response study is intended to begin with multiple doses (sometimes many) across a range. The number of dose groups is adaptively decreased during the course of the study, using the accruing efficacy or safety data in a prospectively specified plan for design modification at one or more unblinded interim analyses" [933] [934] [935] [936] .
OUTCOME DEPENDENT RANDOMIZATION
This approach is particularly valuable in exploratory studies with the "...objective of dose-response evaluation. The method allocates fewer subjects to doses that appear to have a low probability of a treatment-related efficacy response, to have a high probability of an adverse event, or to be unlikely to contribute additional information on the shape of the dose response profile" [986-989].
ADAPTATION OF SAMPLE SIZE
Not well understood if it involves unblinding. See Question 12.
ADAPTATION OF PATIENT POPULATION
"Adaptive methods that have been proposed include (1) changing only the eligibility criteria, with no change in the study overall sample size and with the final analysis including the entire study population, or (2) modifying the plan for the final analysis to include only patients with the preferred characteristic" [1100-1103].
ADAPTATION FOR ENDPOINT SELECTION
"Primary endpoint revision usually takes one of two forms, replacement of the designated primary endpoint with an entirely new endpoint, or modification of the primary endpoint by adding or removing data elements to the endpoint (e.g., the discrete event types included in a composite event endpoint" [1125 -1128] .
ADAPTATION OF MULTIPLE STUDY DESIGN FEATURES IN A SINGLE STUDY
"When multiple adaptations are planned within a single study, the study will become increasingly complex and difficult to plan, with increased difficulty in interpreting the study result. In addition, if there are interactions between the changes in study features, multiple adaptations can be counterproductive and lead to failure of the study to meet its goals" [1155-1158].
WHAT ARE SOME SPECIAL ADAPTIVE DESIGN CONSIDERATIONS IN NON-INFERIORITY STUDIES?
According to the guidance "many design features of a non-inferiority study may not be suitable for adaptation. Chief among these features is the noninferiority margin" The guidance encourages "sample size adjustment using blinded methods to maintain desired study power" [699-671].
"Examination of baseline characteristics of the accumulating study population might show that the expected population is not being enrolled and that by modifying eligibility criteria, subsequent subject enrollment may be shifted towards a population with greater numbers of patients with the desired characteristics. Similarly, if the study enrollment rate is substantially slower than expected, the screening log can be examined for noncritical entry criteria that might be modified to allow greater numbers of screened patients to qualify" [617-623].
ADAPTATIONS TO MAINTAIN STUDY POWER BASED ON BLINDED INTERIM ANALYSES OF AGGREGATE DATA
"In studies using a discrete outcome (event) endpoint, a blinded examination of the study overall event rate can be compared to the assumptions used in planning the study" [652] [653] .
"For studies using a time-to-event analysis, another approach is not to plan a specific study 664 sample size in the protocol, but rather to continue patient enrollment until a prospectively 665 specified number of events has occurred (an event-driven study)" [663-665].
"Similarly, when a continuous outcome measure is the study endpoint, a blinded examination of the variance of the study endpoint can be made and compared to the assumption used in planning the study" [668] [669] [670] . 
ADAPTATIONS USING GROUP SEQUENTIAL METHODS AND UNBLINDED ANALYSES FOR EARLY STUDY TERMINATION BECAUSE OF EITHER LACK OF BENEFIT OR DEMONSTRATED EFFICACY
FDA has concerns but they can be mitigated by a properly constituted DMC. "Implementation of group sequential design methods involves unblinded analyses of the treatment effect, thereby raising significant concerns for potentially introducing bias into the conduct of the study or into subsequent decisions regarding the conduct of the study. Protocols using group sequential designs have addressed this concern by using a committee independent of the study's conduct and sponsor to examine these analyses in a secure and confidential manner. An independent, nonsponsor-controlled Data Monitoring Committee (DMC) (see the DMC guidance) is an inherent part of the group sequential method's protection of study integrity" [817] [818] [819] [820] [821] [822] [823] . See also Question 12.
WHAT HELP IS AVAILABLE FROM FDA FOR ADAPTIVE DESIGNS IN EARLY TO MIDDLE STAGE TRIALS?
Not a whole lot. "Discussion of the plans for an adaptive design study can be the basis for requesting a Type C meeting. FDA's ability to address such requests for studies in early phases of drug development, however, may be limited and will depend on competing workload priorities and on the particulars of the drug and use under development.
Innovative therapeutics for an area of unmet medical need are likely to garner more review attention than other products FDA believes do not fall into this category." [1602-1608].
WHAT HELP IS AVAILABLE FROM FDA FOR ADAPTIVE DESIGNS IN LATE STAGE TRIALS?
Late stage trials may need to be discussed as early as at end of phase 2a: "Depending on the preexisting breadth and depth of information regarding the drug, its specific use, and the nature of the adaptive features, an EOP2 meeting may be the appropriate place in development for initial discussion of an adaptive design A&WC study. However, if there is only limited knowledge of certain critical aspects of the drug's use before conducting the adaptive study, and the study is intended to obtain such knowledge using the study's adaptive features (particularly less well-understood methods), discussion with FDA earlier than usual is advisable (e.g., at a Type C or Endof-Phase 2A meeting). An early meeting for A&WC study protocols with complex adaptive features allows time to carefully consider the plan and to revise and reevaluate it as appropriate, without slowing the clinical development program." [1620] [1621] [1622] [1623] [1624] [1625] [1626] [1627] [1628] .
IS A SPA A GOOD IDEA?
Not really. "If there has been little or no prior discussion between FDA and the study sponsor regarding the proposed study and its adaptive design features, other information requests following initial FDA evaluation are likely and full completion of study assessment within the SPA 45-day time frame is unlikely." [1660] [1661] [1662] [1663] . SPA: Special Protocol Assessment.
WHAT ARE CONCERNS REGARDING THE TYPE I ERROR RATE (FALSE POSITIVES)?
In addition to the well known issues with multiple hypothesis testing, adaptive designs can magnify small biases into large biases: "One type of adaptation based on an unblinded interim analysis of treatment effects is an increase in the study sample size to maintain study power when the observed effect size is smaller than that initially planned in the protocol. When a statistical bias in the estimate of treatment effect exists, an increase in the sample size does not eliminate the bias. Instead, if flaws in the design (or conduct) of a study introduce a small bias, the increase in sample size can result in the bias increasing the Type I error rate more than would occur without the sample size increase. Thus, the impact of small biases can be magnified when sample size increases are enabled." [1233] [1234] [1235] [1236] [1237] [1238] [1239] [1240] [1241] [1242] [1243] [1244] [1245] [1246] .
WHAT ARE RANDOM HIGHS AND UNSTABLE DATA?
"Estimates of the treatment effect are used to make decisions at each stage of an adaptive design study. Because these estimates can be based on a relatively small amount of data, they can be very variable or unstable. The effect estimates for the selected adaptations have the potential to overstate the true effect size because the adaptive choice is usually selected based on the largest of the observed interim treatment effects among the design choice options, which can reflect an unusual distribution of patient observations (often called random highs in group sequential designs). This could also lead to selecting a wrong adaptation choice and thus miss detecting a true treatment effect (i.e., lead to a Type II error "In general, it is best that any SAP updates occur before any unblinded analyses are performed, and that there is unequivocal assurance that the blinding of the personnel determining the modification has not been compromised. A blinded steering committee can make such protocol and SAP changes, as suggested in the ICH E9 guidance and in the DMC guidance, but adaptive designs open the possibility of unintended sharing of unblinded data after the first interim analysis. Any design or analysis modifications made after an unblinded analysis, especially late in the study, may be problematic and should be accompanied by a clear, detailed description of the data firewall between the personnel with access to the unblinded analyses and those personnel making the SAP changes, along with documentation of adherence to these plans." [1367] [1368] [1369] [1370] [1371] [1372] [1373] [1374] [1375] [1376] [1377] 
WHAT ARE SAFETY CONCERNS THAT ARISE IN EARLY PHASE ADAPTIVE DESIGN TRIALS?
Too few patients exposed too fast. Some newer adaptive design algorithms in dose escalation studies "permit a change in dose level after each patient is treated based on the accumulated responses of previously enrolled subjects" and thus "...it is possible to reach the middle or higher end of the doseresponse curve with fewer subjects at each of the prior levels." [1397] [1398] [1399] [1400] [1401] [1402] [1403] . "Where there is little to no prior safety experience with a drug (or related drugs) and the known or hypothetical adverse effects can be serious, however, an adaptive study aggressively designed for most rapidly reaching a decision on the highest tolerable dose might be inappropriate." [1405] [1406] [1407] [1408] . "Study simulations with multiple combinations of escalation criteria, dose-step size, and hypothetical-assumed relationships of exposure to severity and frequency of adverse events may be useful in evaluating different designs." [1413] [1414] [1415] 
WHAT ARE SAFETY CONCERNS WITH ADAPTIVE DESIGNS IN LATE STAGE CLINICAL TRIALS?
Too few patients exposed too early. "Development programs using adaptive design methods are sometimes intended to condense the development program into fewer fully independent studies, with more rapid advancement from small early studies into the large A&WC studies" with only a "...limited amount of safety data available at the time that a large adaptive study is being planned that will entail a great increase in the number of patients exposed to the drug."[1428-1432] "A safety concern that becomes recognized in the data of a moderate-sized study can lead to planning for better evaluation in the A&WC study designed subsequently. The more comprehensive evaluation thus obtained may be necessary to ensure an adequate safety assessment for regulatory review. An adaptive design development program that eliminates the independent mid-sized study and initiates the large adaptive A&WC study before recognizing the safety issue will not have included such additional safety assessments." [1452] [1453] [1454] [1455] [1456] [1457] .
HOW CAN FDA BE REASSURED REGARDING THE PROTECTION OF STUDY BLINDING?
"A failure either to make the appropriate decisions as directed in the prospective SAP or to maintain confidentiality of the interim results might have an adverse impact on the interpretation of the study results. The processes established, as well as how they were performed, should be well documented in the final study report. The ability for FDA to verify compliance, potentially by on-site auditing, may be critical." [1730] [1731] [1732] [1733] [1734] . "This written documentation should include (1) identification of the personnel who will perform the interim analyses, and who will have access to the interim results, (2) how that access will be controlled and verified, and how the interim analyses will be performed, including how any potential irregularities in the data (e.g., withdrawals, missing values) will be managed, and (3) how adaptation decisions will be made. Other issues that should be addressed in these SOPs are (1) 
